The Medicines Company (NASDAQ:MDCO) registered a 3.33% increase, still its new closing price is 35.45% up from the company’s 1 year high of 41.79.It posted 7.07% gains in previous 5 sessions and is now the subject of 1 analysts who together assign a hold rating on stock. 0 of Wall Street analysts have an underperform rating; the 0 sells versus 4 buy or better ratings. The 11 stock analysts following this company have an average price target at $52.18, with individual PT in the $39.00-$65.00 range. The shares moved at $37.25, implying that brokerage firms see shares gaining about 13.36% in twelve months time.
The Medicines Company (MDCO) SEC Form 4 News
The stock is getting much attention these days as insiders are adding shares while they posted a 9.75% rise year to date. A EVP & Chief Corp. Dev. Officer at The Medicines Company (MDCO) acquired shares in a transaction closed on Thursday December 08, 2016. Cox Christopher T bought 105,500 shares in the company at $33.2 each and collected $3,502,001 in proceeds. Cox Christopher T now owns 204,825 shares in the company after this transaction. A Director in the company, ESHELMAN FREDRIC N, disclosed a transaction on Thursday December 08, 2016 that ended up paying $20,995,000 from the purchase of 621,720 shares at $33.77 per share.
The Medicines Company (NASDAQ:MDCO) Upcoming Results on Tap
The Medicines Company will next provide financial results for the March 2017 quarter. Stock analysts expect it to report per-share earnings of $-1.36 in that period. Sales during the quarter are predicted to arrive at $31.6 million.
Earnings surprise history: Last quarter, the company posted approximately $37.6 million in revenue and EPS of $-1.23. The mean forecast was for $37.26 million and $-1.39 a share, respectively. One quarter earlier, revenue for the stock was at $54.73 million, with earnings at $-1.08/share.
The Medicines Company (MDCO) Brokerage Update
The Medicines Company (MDCO) is in Jefferies’s research list so their analyst rating change is noteworthy. These shares were upgraded to Buy from Hold by Jefferies, according to news reported on Friday August 28, 2015.Another important research note was issued by Mizuho on Monday July 06, 2015.The firm upgraded MDCO to Buy from Neutral. Over the last six months and over the last three months, the shares of The Medicines Company (MDCO), have changed -3.72% and 13.05%, respectively.
